

LIST OF FH REB APPROVED POLICIES

Contents

<u>Policy1</u> FH REB POLICY #1:	<u>Requirement for Research Protocol</u>
<u>Policy2</u> FH REB POLICY #2:	<u>Telephone Contact For Obtaining Consent in Emergency Situations</u>
<u>Policy3</u> FH REB POLICY #3:	<u>Exclusion of Remuneration From Recruitment Materials</u>
<u>Policy4</u> FH REB POLICY #4:	<u>Provision of Pre- and Post-Test Counselling</u>
<u>Policy5</u> FH REB POLICY #5:	<u>Information Required For Subjects Identified As High Risk As A Result Of Genetic Status</u>
<u>Policy6</u> FH REB POLICY #6:	<u>Disclosure of Reasons For Not Receiving Study Treatment After Subject Research Participation is Completed</u>
<u>Policy7</u> FH REB POLICY #7:	<u>Identifiers Not Permitted On Study Related Documents</u>
<u>Policy8</u> FH REB POLICY #8:	<u>Translated Consent Forms</u>
<u>Policy9</u> FH REB POLICY #9:	<u>Criterion for Permitting Mandatory Tissue Banking</u>
<u>Policy10</u> FH REB POLICY #10:	<u>Voluntary Donation Of Tissue For Unspecified Uses</u>
<u>Policy11</u> FH REB POLICY #11:	<u>Confidentiality</u>
<u>Policy12</u> FH REB POLICY #12:	<u>Compensation for Injury</u>
<u>Policy13</u> FH REB POLICY #13:	<u>FH REB Approval Statements in Consent Form</u>
<u>Policy14</u> FH REB POLICY #14:	<u>Use of "Negative Consent" Check Boxes in Consent and Assent Forms</u>
<u>Policy15</u> FH REB POLICY #15:	<u>Co-Investigators Listed on Consent Forms</u>
<u>Policy16</u> FH REB POLICY #16:	<u>Conflict of Interest</u>
<u>Policy17</u> FH REB POLICY #17:	<u>Obtaining Assent From Subjects Who Are Legally Incompetent</u>
<u>Policy 18</u> FH REB POLICY #18:	<u>Disclosure of Research-Related Harms for Clinical Trials</u>

Research Ethics Board

Requirement for Research Protocol

Policy No. 1

Approved 12 April 2005
Revised 18 November 2008

The FH REB requires that a research protocol/research plan be submitted for all types of studies, including pilot studies and retrospective chart reviews. The research proposal submitted to granting agencies may be used to meet this requirement; in this case, ensure that the appropriate section of the grant application is referenced. For all other studies, including those that are submitted for expedited review, investigators must submit a protocol that includes the following components:

1. Table of Contents
2. Study Protocol Summary or Abstract
3. Background Information
4. Purpose of Study
5. Hypothesis (if applicable)
6. Justification for Study
7. Objectives of study
8. Research Method (including data collection methods)
9. Sample Size
10. Statistical Analysis Plan
11. Justification if the study has a placebo-control (if applicable)
12. (refer to <http://www.cihr-irsc.gc.ca/e/25139.html> for appropriate use of placebos in clinical trials in Canada)
13. Subject Inclusion Criteria,
14. Subject Exclusion Criteria
15. Research Procedures
16. Potential Benefits
17. Subject Safety Provisions, i.e. un-blinding, data monitoring, and stopping rules

Research Ethics Board

Telephone Contact For Obtaining Consent in Emergency Situations

Policy No. 2

Approved 12 April 2005
Revised 12 February 2010

The FH REB does not allow initial contact by telephone, except under unusual circumstances where timely consent is required, but no Temporary Substitute Decision Maker (TSDM) can be present in that time-frame.

1. This consenting procedure may be used only when the principal investigator or designate cannot speak to the TSDM in person. Telephone contact may be allowed if the TSDM has not arrived with the potential study subject and is not expected at the hospital within the time limit of the study initiation.
2. The principal investigator or designate will present the information in the consent form over the phone and provide any clarification required.
3. Once the TSDM of the patient has been fully informed of the patient's medical condition by the attending physician, the study will be discussed by one of the Investigators. The Principal Investigator or Co-investigator will read the entire consent form over the telephone and provide any clarification requested by the TSDM.
4. When all questions have been answered to the satisfaction of the TSDM, the call will be terminated to provide an opportunity for the TSDM to consider the study. Once a minimum of 30 minutes have passed, the Investigator (and witness) will again contact the individual for their decision (This is done so the family does not have to bear the costs of long distance charges).
5. A witness to the telephone consent, in addition to the Investigator reading the consent form, will be on the telephone line to hear the reading of the consent form and the verbal granting or refusal of consent by the TSDM.
6. The identity of the witness will be disclosed to the TSDM prior to the reading of the consent form.
7. The date and time that the telephone consent is obtained, the names of the TSDM, the Investigator (reader), and the witness will be entered into the original consent form.
8. Whenever possible the consent form will be emailed and/or faxed to the TSDM prior to the reading of the form, enabling them to follow along as it is read to them. If the TSDM agrees to participate they will be instructed to sign the form and fax it back to the principal investigator. If the TSDM does not have access to a fax, the TSDM may send an email acknowledging that he/she has received and read the consent form and is agreeing to allow the subject to participate in the study. Following the email, the signed consent form should be sent to the principal investigator by mail.
9. Written evidence of consent will subsequently be obtained in a timely manner after obtaining verbal consent.

Research Ethics Board

Remuneration in Recruitment Materials

Policy No. 3

Approved 12 April 2005
Revised 18 November 2008

Recruitment materials that are used for the purpose of recruiting subjects, such as letters, advertisements, flyers, radio or television scripts, or internet messages, must not include any information about the value of the remuneration for participation.

Minimal risk studies – The FHREB believes that it is acceptable to advertise the details of reasonable remuneration for participation in minimal risk studies that involve interviews, focus groups or the completion of questionnaires or other types of non-invasive data collection given the understanding that there is no expected benefit from this type of research. Refer to **GN 15** for guidance on the acceptable value of the remuneration.

Research Ethics Board

Provision of Pre- and Post-Test Counseling

Policy No. 4

Approved 12 April 2005

If in the course of research, there are tests that might have results that impact seriously on the research subject's health or have other serious implications (e.g. HIV or some genetic tests), appropriate pre- and post-test counseling services shall be made available to that person, and, when appropriate, to his or her family.

Research Ethics Board

Information Required For Subjects Identified As High Risk As A Result Of Genetic Status

Policy No. 5

Approved 12 April 2005

The consent form must include a statement that informs subjects that any knowledge gained from the research study, that identifies the subjects as belonging to a high-risk group, may reduce the ability of the subject to obtain health and/or life insurance.

The only reason not to tell the subject about this potential risk is if the risk of developing the disease is high based on family history and is not heightened by knowing their genetic status.

Research Ethics Board

Disclosure of Reasons For Not Receiving Study Treatment After Subject Research Participation is Completed ¹

Policy No. 6

Approved 12 April 2005

The following statement shall be required in the Consent Form for any trial involving any drug or other experimental therapy, which is of a chronic nature:

"AFTER THE STUDY IS FINISHED:

You may not be able to receive the study treatment after your participation in the study is completed. There are several possible reasons for this, some of which include: The treatment may not turn out to be effective or safe. The treatment may not be approved for use in Canada. Your caregivers may not feel it is the best option for you. You may decide it is too expensive and insurance coverage may not be available."

¹ These policies have been adopted by the FH REB with the permission of the University British Columbia Clinical Research Ethics Board

Research Ethics Board

Identifiers Not Permitted On Study Related Documents

Policy No. 7

Approved 12 April 2005
Revised 18 November 2008

The FHREB expects that research-related documents (except the master randomization schedule, consent forms, or screening logs) do not include information that would allow the subject to be identified.

Information is considered de-identified if the following conditions are met:

1. the unique study code is not derived from or related to the information about the individual;
2. the unique study code could not be translated to identify the individual, and;
3. the investigator or their institution could not use OR disclose the unique study code for other purposes OR disclose the mechanism for re-identification.

To this end, spaces/fields for subject name, the first or last three letters of a subject's name, actual initials, reversed initials, birth date, hospital medical record number, provincial personal health number, social insurance number, address or phone number are not permitted on study-related documents. Because many other people know/could access these identifiers, they provide less protection of privacy than the use of a unique study code.

Date of Birth: The FHREB will accept the use of month and year only, as an identifier.

It is not necessary to use a personal identifier (for example, birth date) as a secondary identifier in order to confirm the identity of the subjects. This can be accomplished by using any two unique study codes.

Subject Enrollment Logs, documents or databases, which correlate subject names with study code numbers, must be kept on the locked premises of the Principal Investigator or in an appropriately secured electronic form.

Research Ethics Board

Translated Consent Forms

Policy No. 8

Approved 12 April 2005

Translated copies of the consent form(s) will be required for acknowledgement after the FHREB has approved the English version of the consent form. A copy of the translator's signed and appropriate confirmation of the accuracy of the translation must accompany this; or,

Consent forms originally written in other languages must be translated into English and the back translation submitted for ethical review. (Updated 24 September 2004)

If a translator enrolling a subject is using an English consent form, the consent form must include the signature and printed name of the translator and the name of the language it was translated into.

Research Ethics Board

Criterion for Permitting Mandatory Tissue Banking

Policy No. 9

Approved 12 April 2005
Revised 18 November 2008

Tissue is defined as including blood. Mandatory tissue banking is only permitted if the tissue is being banked for purposes **directly related** to the study at hand (i.e. the tissue banking must be integral to the study, such that there would be no study if the subject did not contribute the tissue).

It is unethical to *require* that subjects agree to allow their tissue to be banked for future use or experimentation that is unspecified or unrelated to the study at hand as a condition for entry into a therapeutic trial, as this could be perceived as a coercive method of obtaining tissue/blood samples through offering a perceived therapeutic opportunity.

Research Ethics Board

Voluntary Donation Of Tissue For Unspecified Uses

Policy No. 10

Approved 12 April 2005

Subjects *may* donate their tissue for future, unspecified uses provided:

1. this condition is made explicit in the main consent form for the study;
2. that such donation is optional, and;
3. that the Investigator discloses whether or not they plan to seek the subjects' consent for future projects involving their tissue.

Research Ethics Board

Confidentiality

Policy No. 11

Approved 12 April 2005
Revised 18 November 2008

The following requirements must be in place in order to protect subject confidentiality, but at the same time to allow monitoring of any study to occur. The consent form must include the following, as applicable, along with an explanation about the type of information that will be collected about the research subject.

a. De-identification:

An explanation of how the subject's information has been de-identified. If de-identified, the consent form must explain what type of unique code is used and an explanation that the list that links/matches the subject's name to the unique code and therefore to the subject's research-related information is kept by the principal investigator and/or designate ONLY, under secure conditions, so that it cannot be accessed by unauthorized personnel. See Standard Confidentiality Wording below.

OR

b. Use of Non-standard Identifiers:

When sponsors require that identifiers other than a unique study code be used on research records, justification for such use including their intended use must be provided to the FHREB. Include details of how the subjects' confidentiality will be protected despite the use of the non-standard identifiers. The following standard wording is required and should be added to the Standard Confidentiality Wording as appropriate:

"It is unusual to include [name the non-standard identifier(s), e.g. date of birth/reversed initials] on research records and material forwarded to others. Most studies submit information identified by code numbers or letters only."

OR

c. Anonymization:

If the information is anonymized such that it does not include any identifiers, the consent form must explain that the research information will not identify the subject in any way. The following standard wording is required:

"Your research-related information will not identify you in any way because all identifying information has been removed such that the information is now anonymous and there is no possibility of linking your identity to your information."

d. Availability of Records For Monitoring:

Records must be made available to a scrutineer from an industry sponsor (in the case of sponsored clinical trials), Health Canada (in the case of regulated clinical trials), the U.S. Food and Drug Administration (in the case of American regulated clinical trials), and the Fraser Health Research Ethics Board, provided that it is done in the presence of the Principal Investigator or his or her designate and that the records are not copied or the names recorded. The consent form must explain that identifiable information from source research-related records may be inspected for regulatory, legal and ethical review requirements. See standard wording below:

e. Standard Wording for Confidentiality Disclosures:

"Your confidentiality will be respected. You will be assigned a unique study code [add DOB if this is required and justified] as a subject in this study. [Add DOB disclaimer if required]. Only this number [and DOB] will be used on any research-related information, including medical records, personal data and research data, collected about you during the course of this study, so that your identity [i.e. your name or any other information that could identify you] as a subject in this study will be kept confidential. Information that directly discloses your identity will remain only with the Principal Investigator and/or designate. The list that matches your name to the unique study code [and DOB] that is used on your research-related information will not be released without your knowledge and consent unless required by law or regulation.

No information that discloses your identity will be released or published without your specific consent to the disclosure. However, research records and medical records identifying you may be inspected in the presence of the Investigator or his or her designate by representatives of (name the sponsoring company if relevant), Health Canada (if relevant), (the U.S. Food and Drug Administration, if relevant), and the FH and /or FH Research Ethics Board for the purpose of monitoring the research. These personnel are required to keep your identity and personal information confidential. However, no records which identify you by name will be allowed to leave the Investigators' offices."

If DOB is required, add the following standard wording AFTER the second sentence in the confidentiality wording above in bold text:

Personal information that is recorded in any way other than with a unique study code can potentially reveal your identity. The risk of this is minimal, but possible. In research studies, it is an exception to include date of birth on research records and material forwarded to others. This research study is requesting your consent to use your date of birth. Your signature will indicate your consent to include this information.

f. Research-related Records Leaving the Research Site:

For studies, which require that information be copied, or leave the FH site, include an explanation in the consent form that states specifically what information is leaving the site and where it is going. Note that this explanation should be consistent with the explanation about

the use of identifiers, if any.

g. Research-related Records Sent Outside of Canada

For studies which have identifiable information that is sent outside of Canada, the following standard wording is required:

"I understand that as part of the [Name of Study] research study to which I have consented, identifiable information about me [indicate if this also includes tissue/blood specimens] will be sent to [specify the name and location of the foreign institution or organization]. This organization may be subject to laws that may require access to your personal information, for example, the Patriot Act in the United States. [Updated 2008 July 08] I have been informed that the BC Freedom of Information and Protection of Privacy Act (FOIPPA) prohibits the disclosure of personal information outside of Canada without my consent. All the questions I have asked have been answered in a satisfactory manner and I consent to the disclosure of the information as described during the duration of this study from the date of my signature below."

h. Archiving Research Records:

When investigators must archive research records off-site, they are responsible for the security and confidentiality of the data. The FHREB still considers the data to be "in the Investigators' offices" for the purposes of the wording used in the confidentiality statement.

i. Mandatory Disclosure of Subject's Identity: Reportable Communicable Diseases/Suspected Child Abuse:

In rare instances it will not be possible to ensure confidentiality because of mandatory reporting laws (e.g., suspected child abuse, reportable communicable diseases, and knowledge of harm to others). When this is the case, the prospective research subject should be made aware of this limitation in the consent form.

The BC Health Act Communicable Disease Regulation Schedules A & B list reportable diseases. Sections 2(1), 2(2) and 2(3) require physicians/researchers to report communicable diseases (e.g. HiV, HCV) to the Medical Health Officer. Reporting includes the name, age, sex and address of the infected person.

The only exception to mandatory reporting is for persons who voluntarily submit to testing for HiV; for which a non-nominal report is permitted (i.e. the report must omit the name and address of the person if that person so chooses).

Anonymous surveys that are unlinked do not fall within the reporting requirements of the Act as the physician/researcher would not know that any particular individual was infected.

Standard wording is required for any research studies in which blood tests may reveal the presence of a communicable disease that is reportable by law. Refer to the BC Health Act Communicable Disease Regulation Schedules A & B for the list of reportable diseases at

http://www.qp.gov.bc.ca/statreg/reg/H/Health/4_83.htm.

In addition, standard wording is also required for notification of suspected child abuse for studies involving children.

Required Wording: Use the standard wording for either blood tests for communicable diseases [see a below] OR studies involving children or harms to others [see b below] that is applicable to the study.

"In most cases, your personal information or information that could identify you will not be revealed without your express consent. However, if as a result of your participation in this study, facts become known to the researchers which must be reported by law to public health authorities or legal authorities, then your personal information will be provided to the appropriate agency or authority".

[a] *This requirement applies to communicable diseases which include but are not limited to, hepatitis B or C, West Nile Virus and Human Immune Virus [HIV].*

[b] *Similarly, information that leads the researchers to strongly suspect that a child or others are being harmed or in danger of being harmed, may have to be disclosed by law. Also, information that leads the researchers to strongly suspect that [you/your condition/the subject] may cause serious risk of imminent bodily harm to either [yourself/themselves] or another person may result in immediate action to protect your safety and may require your information and circumstances to be disclosed. [Updated 2008 June 10]*

Except for the circumstances described above the risk of disclosure of personal information is usually very small".

j. Potential for Breach of Confidentiality:

The following statement concerning the possibility of a breach of confidentiality is permissible in the consent form: **"Your personal information may be disclosed if required by law"**. This wording means that there is an absolute obligation to keep confidentiality until such time as there is an exception arising out of a legal requirement to disclose a subject's identity. Other wording, i.e. "to the extent permitted by law" is generally not permissible as this implies that there is not an absolute obligation to keep confidentiality.

k. Photography, Video/Audio Taping:

If there are any plans to use photography (including digital photographs), video or audio taping in the research, who will have access to the recordings and the methods used to protect the subject's identity must be described in the consent form. The eventual fate of the records must also be disclosed (i.e. where and for how long they will be stored and whether they will be destroyed, any plans for secondary uses of the recordings). If there are plans to use these materials for any other purpose than the research project (e.g. for teaching purposes) and subjects could be identified, separate consent is required.

l. Disclosure of Inclusion of Signed Consent Form in Subject's Health Record:

If the subject is a patient in an institution (e.g. hospital) when the research is conducted, inclusion of the signed Consent Form in their permanent health record in Fraser Health is required and if so, this must be disclosed in the Consent Form. The requirement for inclusion of the Consent Form in the health record may vary between other non-FH institutions, and investigators should seek clarification from the institutions involved.

m. Disclosure of Test Results in Subject's Health Record:

If it is the intention or a likely consequence of the research that test results which might affect treatment decisions or have important implications (e.g. HIV tests, genetic tests) will become part of the subject's health record, this must be disclosed in the Consent Form.

Research Ethics Board

Compensation for Injury

Policy No. 12

Approved 12 April 2005
Revised 12 February 2008
Revised 18 November 2008

The following wording will be required to appear in the subject consent form under the Compensation for Injury section:

"By signing this form, you do not give up any of your legal rights and you do not release the study doctor or other participating institutions from their legal and professional duties. *There will be no costs to you for participation in this study*¹. You will not be charged for any research procedures. If you become ill or physically injured as a result of participation in this study, medical treatment will be provided at no additional cost to you. The costs of your medical treatment will be paid by your provincial medical plan and/or *by the study sponsor*. * *[Name the Sponsor]*².

¹ *include if statement is true for this study, i.e. all parking, mileage expenses are being reimbursed to the study subject.*

² *not necessary for non-regulated studies or unfunded studies"*

*Definition of "Sponsor" Refer to ICH Good Clinical Practice Guidelines (ICH GCPs) (1997) [Updated 2008 August 08] http://www.ich.org/MediaServer.jsr?@_ID=482&@_MODE=GLB

The following statements are not permitted because they may be seen to limit the circumstances under which compensation for injury is available:

"Although no funds have been set aside to compensate me in the event of illness or injury related to the study treatment or procedures" OR "While participating...through to "guarantee full coverage", OR There will be no financial compensation..." for damages (e.g. lost time from work, disability or discomfort)" OR "compensation for.... is not routinely available."

Research Ethics Board

FH REB Approval Statements in Consent Form

Policy No. 13

Approved 12 April 2005

The FH REB accepts (but does not require) references in consent forms to the project having been reviewed and/or approved by the Research Ethics Board. When mentioning the Research Ethics Board, the FH REB accepts (but does not require) an explanation of the Board's role in terms similar to the following: "This Board aims to help protect the rights of research subjects."

Note that no mention of risks will be accepted in describing the role of the REB so as to avoid the misinterpretation that the REB's oversight makes it safe for subjects to participate in the research.

Research Ethics Board

Use of "Negative Consent" Check Boxes in Consent and Assent Forms

Policy No. 14

Approved 12 April 2005

The use of "Yes/No" check boxes for consent is not allowed. Lack of signature on a consent form is taken as evidence of dissent, and no subject shall be required to declare in writing in any way that they do not consent to participate in a research project.

Exception to #1:

1a. Where a single consent form contains multiple optional sub-components, (e.g. tissue banking for genetic research) where subjects can choose which ones they wish to participate in, the optional SUB-COMPONENTS (but not the main question of consent to participate in the main project) may employ "Yes/No" indicators to signify willingness to participate.

Lack of indication of "Yes" (or equivalent) shall be taken as evidence of DISSENT and no requirement to check "No" (or equivalent) is allowed.

The FH REB may require that *separate* consent forms fully describing a sub-component(s) of a project be required instead of allowing the procedure described in 1(a) where necessary.

Research Ethics Board

Co-Investigators Listed on Consent Forms

Policy No. 15

Approved 12 April 2005
Revised 11 March 2008

1. The FHREB prefers that all co-Investigators, their institutional affiliation (i.e. use the local site in a multi-site trial) and appropriate titles be listed after the Principal Investigator on both page 1 and the Subject Consent to Participate page of the consent form. (The purpose of including all investigators names is to enable release of health records to any investigator in the study team for that subject.)
2. Where it is not practical to do so, the Board accepts that only the Principal Investigator (including their telephone number) be listed on the consent form.
3. Where a subject's "study doctor" is other than the Principal Investigator, a place must be provided in the consent form for this person to be named, and their telephone number provided.
4. Choice of listing of the Principal Investigator and co-investigators does not affect the requirement for an emergency 24 hour contact number for subjects enrolled in the research.

Research Ethics Board

Conflict of Interest

Policy No. 16

Approved 12 April 2005

At a minimum, potential conflicts must be disclosed to the Board and to potential subjects. The Board may require further action of the researcher to minimize or abandon a conflict, require formal oversight procedures for the research (including audits, independent data safety monitoring processes, regular reports to the FH REB), or may disallow the research altogether. The Board may also inform the investigators' Department Head or Dean of Faculty about the conflict of interest.

Research Ethics Board

Obtaining Assent From Subjects Who Are Legally Incompetent

Policy No. 17

Approved 12 April 2005
Revised 18 November 2008

The FHREB requires researchers to ascertain the willingness of individuals to participate in the research if they are legally incompetent but can nevertheless understand the nature and consequences of the research. These individuals will normally be required to assent by verbal or physical means or to sign an assent form before they can participate in research. These requirements may apply even though free and informed consent has been obtained, or is available, from an authorized third party.

Research Ethics Board

Disclosure of Research-Related Harms for Clinical Trials

Policy No. 18

Approved 12 April 2005
Revised 18 November 2008

The FHREB requires that research-related harms must be identified and quantified in the subject consent form. Any risks related to standard care must be identified and explained to the subject by their study doctor. An explanation of this must be included in the consent form when standard care is involved.

EXCEPTION: The FHREB may require the risks of standard care to be identified and quantified in comparison with those of experimental procedure if that standard of care required in the protocol is not the standard of care currently used in the Fraser Health Authority. This decision will be made on a case by case basis and will be at the discretion of the FHREB. The principal investigator will be informed of any such decision by the FHREB.